Cargando…

Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus

The lack of a licensed vaccine for respiratory syncytial virus (RSV) can be partly attributed to regulatory hurdles resulting from vaccine enhanced respiratory disease (ERD) subsequent to natural RSV infection that was observed in clinical trials of formalin-inactivated RSV (FI-RSV) in antigen-naïve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Killikelly, April M., Kanekiyo, Masaru, Graham, Barney S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040956/ https://www.ncbi.nlm.nih.gov/pubmed/27682426 http://dx.doi.org/10.1038/srep34108

Ejemplares similares

Effects of Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) in the Perinatal Lamb Model of RSV
por: Derscheid, Rachel J., et al.
Publicado: (2013)

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
por: Rossey, Iebe, et al.
Publicado: (2017)

A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus
por: Stewart-Jones, Guillaume B. E., et al.
Publicado: (2015)

Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state
por: Rossey, Iebe, et al.
Publicado: (2017)

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein
por: Tian, Daiyin, et al.
Publicado: (2017)

Summary of the National Advisory Committee on Immunization (NACI) statement update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants
por: Moore, Dorothy, et al.
Publicado: (2022)

Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates
por: Liu, Xueqiao, et al.
Publicado: (2020)

Challenges and Opportunities for Respiratory Syncytial Virus Vaccines
por: Graham, Barney S., et al.
Publicado: (2013)

Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice
por: Rey, Gertrud U., et al.
Publicado: (2013)

Natural Killer and CD8 T Cells Contribute to Protection by Formalin Inactivated Respiratory Syncytial Virus Vaccination under a CD4-Deficient Condition
por: Ko, Eun-Ju, et al.
Publicado: (2020)

The Optimal Concentration of Formaldehyde is Key to Stabilizing the Pre-Fusion Conformation of Respiratory Syncytial Virus Fusion Protein
por: Zhang, Wei, et al.
Publicado: (2019)

A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein
por: Mousa, Jarrod J., et al.
Publicado: (2017)

Inactivation of respiratory syncytial virus by zinc finger reactive compounds
por: Boukhvalova, Marina S, et al.
Publicado: (2010)

Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus
por: Boyington, Jeffrey C., et al.
Publicado: (2016)

Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein
por: Cullen, Lori McGinnes, et al.
Publicado: (2015)

2712. Respiratory syncytial virus (RSV) pre-fusion F antibody titers in hematopoietic cell transplant recipients with upper versus lower respiratory tract infections
por: Kim, Sara R, et al.
Publicado: (2023)

Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus
por: Sastry, Mallika, et al.
Publicado: (2017)

Aerosol Survival, Disinfection and Formalin Inactivation of Nipah Virus
por: Smither, Sophie J., et al.
Publicado: (2022)

Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine
por: Joyce, M. Gordon, et al.
Publicado: (2016)

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
por: Roymans, Dirk, et al.
Publicado: (2017)

Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus
por: Liu, Changbao, et al.
Publicado: (2007)

Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
por: Fries, Louis, et al.
Publicado: (2017)

Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge
por: Park, Soojin, et al.
Publicado: (2018)

Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates
por: Isaacs, Ariel, et al.
Publicado: (2021)

Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein
por: Sun, Zhiwu, et al.
Publicado: (2013)

A single amino acid in the F(2) subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity
por: Lawlor, Heather A., et al.
Publicado: (2013)

Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness
por: Mazur, Natalie I, et al.
Publicado: (2019)

Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B
por: Joyce, M. Gordon, et al.
Publicado: (2019)

Respiratory Syncytial Virus
por: Fraire, Armando E., et al.
Publicado: (2013)

Respiratory syncytial virus
por: Ruuskanen, Olli, et al.
Publicado: (1993)

Respiratory syncytial virus
por: Munoz, Flor M., et al.
Publicado: (2020)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
por: Papenburg, Jesse, et al.
Publicado: (2012)

Discovery of N-Containing (-)-Borneol Esters as Respiratory Syncytial Virus Fusion Inhibitors
por: Sokolova, Anastasiya S., et al.
Publicado: (2022)

Ozone inactivation of airborne influenza and lack of resistance of respiratory syncytial virus to aerosolization and sampling processes
por: Dubuis, Marie-Eve, et al.
Publicado: (2021)

Gamma Irradiation-Inactivated Respiratory Syncytial Virus Vaccine Provides Protection but Exacerbates Pulmonary Inflammation by Switching from Prefusion to Postfusion F Protein
por: Chen, Fengjia, et al.
Publicado: (2023)

Virus-like Particle Vaccine Expressing the Respiratory Syncytial Virus Pre-Fusion and G Proteins Confers Protection against RSV Challenge Infection
por: Lee, Su-Hwa, et al.
Publicado: (2023)

Development of surface engineered antigenic exosomes as vaccines for respiratory syncytial virus
por: Hong, Suyeon, et al.
Publicado: (2021)

Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein
por: Branigan, Patrick J, et al.
Publicado: (2005)

Molecular Epidemiology and Phylodynamics of the Human Respiratory Syncytial Virus Fusion Protein in Northern Taiwan
por: Chi, Hsin, et al.
Publicado: (2013)

Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein
por: Flynn, Jessica A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k7t7op7rmhsbe2drebnmfjs43v